PDL BioPharma — Q2 2018 Earnings Presentation
12 slides from PDL BioPharma's earnings presentation, Aug 8, 2018
Slide 1: Second Quarter 2018 Financial Results Conference Call
PDL Second Quarter 2018 Financial Results Conference Call August 8, 2018
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements, including PDL's expectations with respectto its future royalty revenues, expenses, net income, and cash provided by operating activities. Each of these forward-looking statements involves risks and uncertainties. Actua
Slide 3: Depomed Agreement — Before and After
Depomed Agreement — Before and After o Original agreement: In October 2013, PDL paid $240.5 million for 100% of royalties and milestones on sales of type 2 diabetes products until cash flows reached $481 million or two times original investment, after which proceeds split evenly between PDL and Depo
Slide 4: Cash Flows from Royalties 2018 to 2022
Cash Flows from Royalties 2018 to 2022 Cumulative cash flows expected to exceed $400 million $120 $450 $400 $ 100 ss s3s0 = z = z sao 3300 & $ $250 = & seo s 2 $200 § Bag $150 2 g 2 & si00 § $20 $50 $s $ 2o1s 2019 2020 2021 2022 Year me Depomed ma U of M- Cordelga mam AceIRx mmm Vicogliosi Brothers
Slide 5: Q2 Noden Impairment Results in a Book Value Decrease of $0.75 vs. Prior Quarter
Q2 18 Noden Impairment Results in a Book Value Decrease of $0.75 vs. Prior Quarter $6.00 $5.75 $5.50 $5.25 $5.00 $4.75 $4.50 $4.25 $4.00 $3.75 $3.50 $3.25 $3.00 $2.75 $2.50 $2.25 $2.00 $1.75 $1.50 $1.25 $1.00 $0.75 $0.50 $0.2! $ PDL’s book value for the period ending June 30, 2018 was $4.85 Sep-13 P
Slide 6: Noden Background
Noden Background Q Noden Pharma = Platform upon which to build a pharmaceutical company. = PDL owns 100% of Noden companies. = Noden already has two products on the market—both indicated for hypertension. o Tekturna® and Tekturna HCT®, as they are known in the U.S., and Rasilez® and Rasilez HCT®, as
Slide 7: Noden: Focus on Profitability
Noden: Focus on Profitability a Reported revenues on the Noden products for Q218 of $25.9 million. = $10.4 million from US sales and $15.5 million from ROW. = 60 percent increase in productrevenues year over year. Q Noden sales successfully stabilized, discontinuing contract sales force and transiti
Slide 8: LENSAR Evolution
LENSAR Evolution ; ~li NaN \ AR NY, IF YOUR FEMTOSECOND CATARACT LASER HASN'T EVOLVED, IT’S PROBABLY EXTINCT Don't let your technology put you at risk for ‘extinction. Manage astigmatism with LENSAR®, now with Streamline? IV. Join the Evolution. [LEARN MORE>
Slide 9: Second Quarter 2018 Financials
Second Quarter 2018 Financials Three Months Ended Six Months Ended June 30, June 30, (In thousands, except per share amounts) 2018 2017 2018 2017 Royalties from Queen et al. patents S 1.218 $ 16.285 S$ 4,001 $ 30,441 Royalty rights - change in fair value 12,842 83.725 23,933 96,871 Interest revenue
Slide 10: Second Quarter 2018 Financials
Second Quarter 2018 Financials GAAP net income (oss) attributed to PDL's shareholders as reported Adjustments: Mark-to-market adjustment to fair value assets Non-cash interest revenues Non-cash stock-based compensation expense Non-cash debt offering costs Mark-to-market adjustment on warrants held I
Slide 11: Second Quarter 2018 Financials
Second Quarter 2018 Financials Condensed consolidated balance sheet (unaudited) June 30, December 31, 2018 2017 Cash, cash equivalents and investments $ 395,653 $ 532,114 Total notes receivable $ 70,887 $ 70,737 Royalty rights - at fair value $ 335,163 $ 349,223 Intangible assets, net $ 54,472 $ 215
Slide 12: Question and Answer Session
PDL Question and Answer Session